| Identification | Back Directory | [Name]
Maytansine, N2'-[3-[[1-[[4-(aminocarbonyl)cyclohexyl]methyl]-2,5-dioxo-3-pyrrolidinyl]thio]-1-oxopropyl]-N2'-deacetyl- | [CAS]
1100692-14-5 | [Synonyms]
Maytansine, N2'-[3-[[1-[[4-(aminocarbonyl)cyclohexyl]methyl]-2,5-dioxo-3-pyrrolidinyl]thio]-1-oxopropyl]-N2'-deacetyl- | [Molecular Formula]
C47H64ClN5O13S | [MOL File]
1100692-14-5.mol | [Molecular Weight]
974.56 |
| Chemical Properties | Back Directory | [Boiling point ]
1152.4±65.0 °C(Predicted) | [density ]
1.37±0.1 g/cm3(Predicted) | [solubility ]
DMSO : 190 mg/mL (194.96 mM; Need ultrasonic) | [form ]
Solid | [pka]
9.82±0.70(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
MCC-DM1 is a agent-Linker Conjugates for ADC such as Anti-CD22-MCC-DM1. MCC-DM1 can be detected in rat and human plasma, feces, and other tissues[1][2]. | [Biological Activity]
MCC-DM1 is a drug-Linker Conjugates for ADC such ad Anti-CD22-MCC-DM1[1]. | [References]
[1]. Manu Lopus, et al. Antibody-DM1 conjugates as cancer therapeutics. Cancer Lett. 2011 Aug 28;307(2):113-8. |
|
|